#USA #Seattle #Breast Cancer #Perimeter Medical #Claire OCT

Perimeter Medical Imaging Unveils Claire™ at ASBrS 2026

Seattle, WA - Perimeter Medical Imaging AI, Inc. has officially unveiled their innovative medical imaging device, Claire™, at the 27th Annual Meeting of the American Society of Breast Surgeons (ASBrS). This advanced technology, which utilizes AI and optical coherence tomography (OCT), has garnered attention as the first AI-enabled imaging system approved by the FDA for intraoperative breast cancer margin assessment. The event, held from April 29 to May 3, serves as a significant platform for medical professionals to learn about breakthroughs in surgical technology.

Revolutionary Features of Claire™

Claire™ has been designed to significantly enhance the surgical experience for breast cancer procedures. It stands out from traditional imaging techniques—with a resolution that is ten times greater than standard X-rays and ultrasounds at a depth of 2mm, which is crucial for accurately assessing tumor margins. Furthermore, the unique AI-capabilities of Claire™ ensure that surgeons can detect even difficult-to-spot cancerous tissues, potentially eliminating the need for follow-up surgeries.

The technology powering Claire™ is based on a database of over 2 million breast tissue images, allowing it to accurately identify abnormalities. As stated by Perimeter's CEO, Adrian Mendes, "We are thrilled to present Claire at ASBrS, a gathering of over 1,700 healthcare professionals. The combination of AI with real-time OCT imaging is expected to significantly improve surgical decisions and patient outcomes."

During the conference, attendees are encouraged to visit Booth #325 where live demonstrations of Claire™ will be available. These sessions aim to provide firsthand experience of its revolutionary capabilities and discuss its potential applications in real-world scenarios.

Implications for the Future of Breast Cancer Surgery

The approval of Claire™ marks a milestone not only for Perimeter but also for the future of breast cancer treatment options. Historically, breast-conserving surgeries have faced challenges regarding margin assessment—an area where Claire™ intends to make a substantial impact. The tool is engineered to integrate seamlessly with typical surgical evaluations and provide its findings concurrently, enhancing the overall surgical strategy.

However, it is vital to note that while Claire™ serves as an adjunct imaging tool, it is not designed to replace traditional histopathology assessments, nor should it be used diagnostically. Understanding these parameters is important as the medical community begins to adopt AI technologies in surgical settings.

Looking Ahead

With its headquarters in both Toronto and Dallas, Perimeter Medical Imaging remains dedicated to advancing medical imaging applications within oncology. Their mission is rooted in transforming how surgeries are conducted, addressing urgent medical needs with innovative solutions like Claire™. As they move forward, Perimeter is committed to continuous improvement and expansion of their technologies, ensuring they meet the highest standards while catering to evolving patient needs.

By joining forces with leading breast cancer organizations and surgeons, Perimeter hopes to further refine Claire™'s algorithms and expand its capabilities through ongoing research and clinical testing.

In conclusion, the unveiling of Claire™ at ASBrS 2026 heralds a new era for breast cancer surgery. With its groundbreaking technology, surgeons may soon find that the dream of eliminating the need for repeat surgeries is within reach. Perimeter's strategic approach and innovative spirit create optimism for the future of cancer treatment, paving the way for improved patient experiences and outcomes in surgical care.